Biosimilars in Action at ASH 2018

Posted by Prateek Yadav on Dec 21, 2018 9:12:11 AM

Amy Leigh Niedzwecki co-wrote this blog post with Prateek Yadav.

At the 2018 Annual Society of Hematology (ASH) Annual Meeting, held Dec. 1-4 in San Diego, biosimilars were often top of mind. Within the hematology and oncology space, Rituxan (rituximab), Neupogen (filgrastim) and Neulasta (pegfilgrastim) are currently the most sought-after biologics for developing biosimilars, and the studies presented at the conference were limited to these three blockbuster biologics.

Here are our top three takeaways from this year’s event:

Read More